National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 456608

History of Changes from the VAERS Wayback Machine

First Appeared on 6/13/2012

VAERS ID: 456608
VAERS Form:
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / - LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.


Changed on 6/14/2014

VAERS ID: 456608 Before After
VAERS Form:
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / - LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.


Changed on 4/14/2017

VAERS ID: 456608 Before After
VAERS Form:
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / - LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.


Changed on 9/14/2017

VAERS ID: 456608 Before After
VAERS Form:(blank) 1
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / - UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.


Changed on 2/14/2018

VAERS ID: 456608 Before After
VAERS Form:1
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.


Changed on 6/14/2018

VAERS ID: 456608 Before After
VAERS Form:1
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.


Changed on 8/14/2018

VAERS ID: 456608 Before After
VAERS Form:1
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.


Changed on 9/14/2018

VAERS ID: 456608 Before After
VAERS Form:1
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.


Changed on 10/14/2018

VAERS ID: 456608 Before After
VAERS Form:1
Age:13.0
Gender:Female
Location:Foreign
Vaccinated:2011-08-18
Onset:2011-09-01
Submitted:2012-05-31
Entered:2012-05-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA143BA / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Completed suicide, Death, Musculoskeletal stiffness

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2011-09-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Carbocisteine; Fexofenadine hydrochloride; Pranlukast
Current Illness: Allergic rhinitis; Congenital heart disease
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0804493A

Write-up: This case was reported by a physician and described the occurrence of suicide in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent medical conditions included allergic rhinitis and congenital heart disease. Concurrent medications included MUCODYNE, ALLEGRA and ONON. On 18 August 2011, the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular, left deltoid). On an unspecified date, as the subject had muscle stiffness, Kakkonto 2.5g twice a day for 3 days and LOXONIN for 6 doses were prescribed. On 1 September 2011, 14 days after vaccination with CERVARIX, the subject committed suicide. The subject died on 1 September 2011 from accomplished suicide. It was unknown whether an autopsy was performed.

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=456608&WAYBACKHISTORY=ON


Copyright © 2019 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166